Meeting Program

13:00–13:15 Opening and welcome

  • Words of welcome
    Konstanze Döhner (Germany)
    Claire Harrison (United Kingdom)
    Shahram Kordasti (United Kingdom)

13:15–14:15 Session 1: Diagnosis, Classification and Risk Assessment in 2026

Chair: Catherine Cargo (United Kingdom)

  • Acute myeloid leukemia
    Hartmut Döhner (Germany)
  • Myeloproliferative neoplasms
    Lina Benajiba (France)
  • Myelodysplastic synsdromes
    Catherine Cargo (United Kingdom)

14:15–15:15 Oral Abstract Session 1: Genomics of MPN, MDS and AML

Chair to be announced

  • DECODING THE MYELOID DISEASE CONTINUUM: MACHINE LEARNING–BASED DEVELOPMENT AND VALIDATION OF A MULTIMODAL INTEGRATING CLASSIFICATION OF MYELOID NEOPLASMS
    Yu-Hung Wang (Taiwan)
  • COMPREHENSIVE CHARACTERIZATION OF SOMATIC PTPN11-MUTATED JMML
    Edoardo Muratore (Italy)
  • LONGITUDINAL COMPREHENSIVE ANALYSIS OF CLONAL EVOLUTION AND TRANSCRIPTOMIC CHANGES TO UNRAVEL DISEASE PERSISTENCE AND EVOLUTION IN MPN
    Conrad Weidt (Germany)
  • LONG-READ TRANSCRIPTOMICS DEFINES SPLICING DEFECTS IN DDX41-MUTATED ACUTE MYELOID LEUKEMIA
    Carolin Seeling (Germany)

15:15–15:30 Coffee break

15:30–16:30 Session 2: Future Diagnostic Platforms and Educational Needs – Data Overload

Torsten Haferlach (Germany) & Matteo Della Porta (Italy)

  • From Data Overload to Better Care: How AI can improve diagnosis and treatment
    Torsten Haferlach (Germany)
  • Digital twins powered by real-world data for explainable and trustworthy personalized medicine
    Matteo Della Porta (Italy)

16:30–17:15 Debate: What to do with an elderly fit patient?

Chair to be announced

  • How can we define fitness in 2026?
    Adriano Venditti (Italy)
  • Standards and emerging options for less intensive therapy in 2026
    Christoph Röllig (Germany)

17:15–17:30 Coffee break

17:30–18:15 Satellite symposium 1

18:15–19:15 Welcome Reception + Poster session

08:00–08:45 Meet the Experts Breakfast

09:00–10:00 Session 3: Genomics in MPN, MDS, AML

Chair: Paola Guglielmelli (Italy)

  • Acute myeloid leukemia
    Lars Bullinger (Germany)
  • Myeloproliferative neoplasms
    Paola Guglielmelli (Italy)
  • Myelodysplastic synsdromes
    Matteo Della Porta (Italy)

10:00–11:00 Session 4: Microenvironment, proteomics, and microbiome

Chair: Dominique Bonnet (United Kingdom)

  • Niche
    Dominique Bonnet (United Kingdom)
  • Microbiome
    Saeed Shoaie (United Kingdom)
  • Proteims and metabolomics
    Speaker to be announced

11:00–11:15 Coffee break

11:15–12:15 Session 5: Immunome in MPN, MDS and AML – What Is It and How to Target?

Chairs: Shahram Kordasti (United Kingdom) & Arjan van de Loosdrecht (Netherlands)

  • Overriding intrinsic inflammation in AML as a therapeutic concept
    Philipp Jost (Austria)
  • Myeloproliferative neoplasms and CHIP
    Dominik Wolf (Austria)
  • Myelodysplastic synsdromes
    Arjan van de Loosdrecht (Netherlands)

12:15–13:30 Lunch break

13:00–13:45 Satellite Symposium 2

13:45–14:45 Session 6: Treatment of MPN in 2026

Chairs: Claire Harrison (United Kingdom) & Jean-Jacques Kiladjian (France)

  • CALR antibody treatment
    Claire Harrison (United Kingdom)
  • MRD included
    Jean-Jacques Kiladjian (France)
  • Transplant in MPN
    Donal McLornan (United Kingdom)

14:45–15:00 Coffee break

15:00–16:00 Session 7: Treatment of MDS in 2026

Chairs: Antonio Almeida (Portugal) & Lionel Ades (France)

  • Low-risk
    Antonio Almeida (Portugal)
  • High-risk
    Maria Teresa Voso (Italy)
  • Novel agents
    Lionel Ades (France)

16:00–16:45 Debate: Immunotherapy in MDS, a finished story?

Chair: Arjan van de Loosdrecht (Netherlands)

  • Debaters
    Shahram Kordasti (United Kingdom)
    Lionel Ades (France)

16:45–17:00 Coffee break

17:00–17:45 Satellite Symposium 3

09:00–10:00 Session 8: Treatment of AML in 2026

Chair: Konstanze Döhner (Germany)

  • Combination therapy using novel drugs for patients fit for intensive therapy
    Bas Wouters (Netherlands)
  • Combination therapy using novel drugs for patients unfit for intensive therapy
    Alessandro Isidori (Italy)
  • Novel aspects of MRD monitoring
    Konstanze Döhner (Germany)

10:00–11:00 Oral Abstract Session 2

Chair to be announced

  • CLINICAL AND MOLECULAR FEATURES OF THERAPY-RELATED AML: A HARMONY PROJECT ANALYSIS
    Luca Guarnera (Italy)
  • SINGLE-CELL MULTI-OMICS REVEALS DISEASE-SPECIFIC REGULATORY T CELL SUBPOPULATIONS IN MYELODYSPLASTIC NEOPLASMS
    Rita Antunes dos Reis (United Kingdom)
  • SURVIVAL BENEFIT OF ALLOGENEIC HSCT IN CMML PATIENTS DURING THE MOLECULAR STRATIFICATION ERA
    Rui Ma (China)
  • IMMUNE MODULATION IN MYELOPROLIFERATIVE NEOPLASMS: DEVELOPMENT OF A MACROPHAGE PHAGOCYTOSIS ASSAY AND ANALYSIS OF TUMOUR-MACROPHAGE INTERACTIONS
    Anya Megan Squires (United Kingdom)
  • HYDROXYUREA-DRIVEN TP53 HEMIZYGOSITY ACCELERATES LEUKEMIC TRANSFORMATION IN CALR-MUTANT MPNS
    Syrine Bel Haj Yahia (France)

11:00–11:15 Coffee break

11:15–12:00 Session 9: Challenging Clinical Cases

Chairs: Alesia Khan (United Kingdom) & Sanam Loghavi (United States)

  • MDS/MPN (case)
    Alesia Khan (United Kingdom)
  • Hematopathologist review
    Sanam Loghavi (United States)
  • Expert panel
    All speakers

12:00–12:15 Closing ceremony

  • Closing remarks
    Konstanze Döhner (Germany)
    Claire Harrison (United Kingdom)
    Shahram Kordasti (United Kingdom)

12:15–13:00 Farewell lunch

 

Share